` ME1 (Melodiol Global Health Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

ME1
vs
S&P/ASX 300

Over the past 12 months, ME1 has underperformed S&P/ASX 300, delivering a return of -86% compared to the S&P/ASX 300's 9% growth.

Stocks Performance
ME1 vs S&P/ASX 300

Loading
ME1
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
ME1 vs S&P/ASX 300

Loading
ME1
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
ME1 vs S&P/ASX 300

Loading
ME1
S&P/ASX 300
Add Stock

Competitors Performance
Melodiol Global Health Ltd vs Peers

S&P/ASX 300
ME1
LLY
JNJ
NOVO B
ROG
Add Stock

Melodiol Global Health Ltd
Glance View

Market Cap
1.1m AUD
Industry
Pharmaceuticals

Melodiol Global Health Ltd is a AU-based company operating in Pharmaceuticals industry. Melodiol Global Health Limited, formerly Creso Pharma Limited, is an Australia-based cannabis company. The firm is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product is offered under various brands, including Green Goo, Southern Butter, Good Goo, Ritual, impactive and cannaQIX, among others. The company cultivates and harvests cannabis plants through its subsidiary, Mernova Medicinal Inc. and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc., it is also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.

ME1 Intrinsic Value
Not Available
Back to Top